Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational design of structure‐based vaccines targeting misfolded alpha‐synuclein conformers of Parkinson's disease and related disorders

9 Apr 2024

Abstract excerpt

Synucleinopathies, including Parkinson's disease (PD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB), are neurodegenerative disorders caused by the accumulation of misfolded alpha-synuclein protein. Developing effective vaccines against synucleinopathies is challenging due to the difficulty of stimulating an immune-specific response against alpha-synuclein without causing harmful autoimmune...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Botulinum Toxin and Related Neurological Disorders
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39036077
DOI: 10.1002/btm2.10665

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational design of structure‐based vaccines targeting misfolded alpha‐synuclein conformers of Parkinson's disease and related disordersPMID 39036077Read ↗

Rational design of structure-based vaccines targeting misfolded alpha-synuclein conformers of Parkinson’s disease and related disordersSemantic proximity Read ↗

A model-based prion vaccine protects a transgenic mouse line carrying a Gerstmann-Sträussler-Scheinker disease mutation.Semantic proximity Read ↗

Rational design of antibodies targeting specific epitopes within intrinsically disordered proteinsSemantic proximity Read ↗

Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody FragmentsSemantic proximity Read ↗

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit <i>in‐vitro</i> seeded aggregation and toxicitySemantic proximity Read ↗

Virally encoded single-chain antibody fragments targeting alpha-synuclein protect against motor impairments and neuropathology in a mouse model of synucleinopathySemantic proximity Read ↗

Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic α-synuclein oligomersSemantic proximity Read ↗

Monoclonal antibodies targeting cytotoxic α-synuclein oligomers: molecular properties and diagnostic potentialSemantic proximity Read ↗

Direct disassembly of α-syn preformed fibrils into native α-syn monomers by an all-D-peptideSemantic proximity Read ↗

Optimizing epitope conformational ensembles using <i>α</i> -synuclein cyclic peptide “glycindel” scaffolds: A customized immunogen method for generating oligomer-selective antibodies for Parkinson’s diseaseSemantic proximity Read ↗

Inhibiting α-synuclein oligomerization by stable cell-penetrating β-synuclein fragments recovers phenotype of Parkinson's disease model flies.Semantic proximity Read ↗

Foldamers Reveal and Validate Novel Therapeutic Targets Associated with Toxic α-Synuclein Self-AssemblySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.